Last Update: Jan 14, 2025
This is a Non-interventional, Prospective, Multicenter Study Conducted in France. The Primary Objective of This Study is to Describe the Quality of Life of MS Patients After Initiation of Treatment With Ofatumumab.
ClinicalTrials.gov Identifier:
Novartis Reference Number:COMB157GFR06
All compounds are either investigational or being studied for (a) new use(s). Efficacy and safety have not been established. There is no guarantee that they will become commercially available for the use(s) under investigation.

Study Description

SEPROS is a non-interventional study, based on primary data collection of MS adult patients who initiated ofatumumab as per neurologist practice and regardless of the study protocol. This is a non-interventional, prospective (primary data), multicenter study conducted in metropolitan France. The primary objective of this study is to describe the quality of life of MS patients after initiation of treatment with ofatumumab.

In order to form a representative sample of MS patients taking into account the terms of care in France, free or practicing neurologists in healthcare institutions (public or private) in different regions of France will be selected to participate in this study.

The study will enroll adult patients with MS who initiated ofatumumab according to the physician's advice and independently of the study. Patients will be followed from initiation of ofatumumab either until (i) 12 months (± 1month) after initiation of ofatumumab (End of Study), or until (ii) discontinuation of treatment with ofatumumab prior to the completion of the 12-month follow-up (early termination); whichever occurs first (end of study or early termination).

Multiple Sclerosis (MS)
Recruiting
294
Dec 21, 2023
Jul 31, 2026
All
18 Years - 99 Years (Adult, Older Adult)

Interventions

Other

ofatumumab

There is no treatment allocation. Participants with MS that initiated treatment with ofatumumabas per neurologist practice and regardless of the study protocol

Eligibility Criteria

Inclusion Criteria:

1. Male or female, 18 years of age or older
2. Patient with confirmed MS diagnosis
3. Patient initiating treatment with ofatumumab for the first time
4. Patient for which the decision to initiate treatment with ofatumumab was made by the doctor (investigator) in accordance with his/her usual practices independently of the study
5. Patient not opposed to participation in this study
6. Patient willing and able to complete patient questionnaires

Exclusion Criteria:

1. Patient treated with ofatumumab in the context of a clinical trial

Novartis Investigative Site

Recruiting

Paris,75017,France

Novartis Investigative Site

Recruiting

Chambery cedex,73011,France

Novartis Investigative Site

Recruiting

Mont de Marsan cedex,40024,France

Novartis Investigative Site

Recruiting

Saverne,67700,France

Novartis Investigative Site

Recruiting

Amiens,80054,France

Novartis Investigative Site

Recruiting

Le Coudray,28630,France

Novartis Investigative Site

Recruiting

Pointe A Pitre,97159,France

Novartis Investigative Site

Recruiting

Compiegne,60200,France

Novartis Investigative Site

Recruiting

Montlucon,03100,France

Novartis Investigative Site

Recruiting

Selestat,67600,France

Novartis Investigative Site

Recruiting

Angers Cedex 9,49933,France

Novartis Investigative Site

Recruiting

Lens,62307,France

Novartis Investigative Site

Recruiting

Poissy,78303,France

Novartis Investigative Site

Recruiting

Altkirch,68130,France

Novartis Investigative Site

Recruiting

Contamine Sur Arve,74130,France

Novartis Investigative Site

Recruiting

Montpellier,34295,France

Novartis Investigative Site

Recruiting

Strasbourg,67000,France

Novartis Investigative Site

Recruiting

Bethune,62400,France

Novartis Investigative Site

Recruiting

Libourne,33505,France

Novartis Investigative Site

Recruiting

Pringy,74374,France

Novartis Investigative Site

Recruiting

Lyon,69275,France

Novartis Investigative Site

Recruiting

Dax,40107,France

Novartis Investigative Site

Recruiting

Nimes,30029,France

Novartis Investigative Site

Recruiting

Toulouse Cedex 9,31059,France

Novartis Investigative Site

Recruiting

Bordeaux Cedex,33076,France

Novartis Investigative Site

Recruiting

Lille,59000,France

Novartis Investigative Site

Recruiting

Mulhouse,68100,France

Novartis Investigative Site

Recruiting

Reims,51092,France

Novartis Investigative Site

Recruiting

La Rochelle,17019,France

Novartis Investigative Site

Recruiting

Orsay,91400,France

Novartis Investigative Site

Recruiting

Brest,29200,France

Novartis Investigative Site

Recruiting

Tours,37044,France

Novartis Investigative Site

Recruiting

Mantes La Jolie,78200,France

Novartis Investigative Site

Recruiting

Valence Cedex 9,26953,France

Novartis Investigative Site

Recruiting

Rennes,35043,France

Novartis Investigative Site

Recruiting

La Seyne Sur Mer,83500,France

Novartis Investigative Site

Recruiting

Paris Cedex 12,F-75571,France

Novartis Investigative Site

Recruiting

Cahors,46000,France

Novartis Investigative Site

Recruiting

Villeurbanne,69100,France

Novartis Investigative Site

Recruiting

Marseille 01,13001,France

Novartis Investigative Site

Recruiting

Agen 09,47923,France

Novartis Investigative Site

Recruiting

Saint Maur Des Fosses,94100,France

Novartis Investigative Site

Recruiting

Le Bouscat,33110,France

Worldwide Contacts

If the location of your choosing does not feature any contact detail, please reach out using the information below.

Novartis Pharmaceuticals